Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹432.8 Cr
verified against source
Revenue YoY
40.3%
reported change
EBITDA
₹183.5 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Acutaas Chemicals delivered a stellar Q4 FY26 with revenue of 432.8 cr (+40.3% YoY) and EBITDA of 183.5 cr (margin 42.4%, +1487 bps YoY), driven by strong CDMO ramp-up, portfolio reshuffling, and operating leverage. PAT more than doubled to 134.3 cr. Management guided for 25% revenue growth in FY27 and stable EBITDA margins, supported by battery electrolyte additive commercialization, four new CDMO products in validation, and recovery in semiconductor chemicals (BFC). The South Korea JV (Indicam) is on track for H2 CY26 commissioning. Key risk: global supply chain disruptions from Gulf conflict could pressure raw material costs and margins.
Colored figures show movement against the previous available record.
Guidance to track
- Management guided for 25% year-on-year revenue growth in FY27, consistent with historical performance.
- Management expects EBITDA margin to remain at similar levels as FY26 (around 35-36%), driven by product mix.
- The CDMO business is expected to reach ₹1,000 cr in revenue by FY28, backed by long-term contracts and pipeline.
- FY27 capex includes ~₹50 cr spillover from FY26 (electrolyte additive and pilot plant) and ~₹40 cr maintenance capex.
Risks flagged
- Ongoing conflict in the Gulf region has disrupted feedstock supply chains and pushed raw material prices higher, potentially impacting margins.
- Analyst raised concern about ₹48 cr goodwill added for Indicam JV, which has no revenue yet. Management expressed confidence but provided no specific recovery timeline.
- Q1 is historically the weakest quarter (H1 ~40% of revenue). Despite CDMO ramp-up, management expects similar seasonality in FY27.
- Analyst asked about risk from sodium-ion battery adoption. Management downplayed near-term impact but acknowledged potential long-term shift.
Key quotes
- We are guiding 25% revenue growth in FY27.
- We are expecting similar kind of margin in FY27 also for us the margin is a function of product mix and we expect similar kind of product mix in FY27.
- We have already got customer contract in place and already signed.
Research modules